FI955721A0 - Expression av inhibitorer för en plasminogen aktivator av urokinastyp - Google Patents
Expression av inhibitorer för en plasminogen aktivator av urokinastypInfo
- Publication number
- FI955721A0 FI955721A0 FI955721A FI955721A FI955721A0 FI 955721 A0 FI955721 A0 FI 955721A0 FI 955721 A FI955721 A FI 955721A FI 955721 A FI955721 A FI 955721A FI 955721 A0 FI955721 A0 FI 955721A0
- Authority
- FI
- Finland
- Prior art keywords
- urokinase
- plasminogen activator
- type plasminogen
- express inhibitors
- inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B40/00—Libraries per se, e.g. arrays, mixtures
- C40B40/02—Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6456—Plasminogen activators
- C12N9/6462—Plasminogen activators u-Plasminogen activator (3.4.21.73), i.e. urokinase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21073—Serine endopeptidases (3.4.21) u-Plasminogen activator (3.4.21.73), i.e. urokinase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2795/00—Bacteriophages
- C12N2795/00011—Details
- C12N2795/00041—Use of virus, viral particle or viral elements as a vector
- C12N2795/00043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Ophthalmology & Optometry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US7015393A | 1993-06-01 | 1993-06-01 | |
PCT/US1994/005669 WO1994028145A2 (en) | 1993-06-01 | 1994-05-19 | Expression of urokinase plasminogen activator inhibitors |
Publications (2)
Publication Number | Publication Date |
---|---|
FI955721A FI955721A (sv) | 1995-11-27 |
FI955721A0 true FI955721A0 (sv) | 1995-11-27 |
Family
ID=22093474
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FI955721A FI955721A0 (sv) | 1993-06-01 | 1995-11-27 | Expression av inhibitorer för en plasminogen aktivator av urokinastyp |
Country Status (12)
Country | Link |
---|---|
US (1) | US6268341B1 (sv) |
EP (1) | EP0802983B1 (sv) |
JP (1) | JPH08508172A (sv) |
KR (1) | KR960702522A (sv) |
AT (1) | ATE239085T1 (sv) |
AU (1) | AU7137994A (sv) |
CA (1) | CA2162855A1 (sv) |
DE (1) | DE69432608T2 (sv) |
FI (1) | FI955721A0 (sv) |
NO (1) | NO954778D0 (sv) |
NZ (1) | NZ268470A (sv) |
WO (1) | WO1994028145A2 (sv) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5519120A (en) * | 1989-04-07 | 1996-05-21 | Cancerforskningsfondet Af 1989 | Urokinase-type plasminogen activator receptor antibodies |
AU7137994A (en) | 1993-06-01 | 1994-12-20 | Chiron Corporation | Expression of urokinase plasminogen activator inhibitors |
US5891742A (en) * | 1995-01-19 | 1999-04-06 | Chiron Corporation | Affinity selection of ligands by mass spectroscopy |
US5942492A (en) | 1996-11-12 | 1999-08-24 | Angstrom Pharmaceuticals, Inc. | Cyclic peptides that bind to urokinase-type plasminogen activator receptor |
US6277818B1 (en) | 1998-10-29 | 2001-08-21 | Angstrom Pharmaceuticals, Inc. | Cyclic peptide ligands that target urokinase plasminogen activator receptor |
US5994309A (en) | 1997-07-25 | 1999-11-30 | Angstrom Pharmaceuticals, Inc. | Anti-invasive and anti-angiogenic compositions and methods |
US6750201B1 (en) | 1997-10-17 | 2004-06-15 | The Trustees Of The University Of Pennsylvania | Compositions and methods for promoting internalization and degradation of urokinase-type plasminogen activator |
CA2306953A1 (en) * | 1997-10-17 | 1999-04-29 | Abd Al-Roof Higazi | Compositions and methods for promoting internalization and degradation of urokinase-type plasminogen activator |
DE69921102T2 (de) * | 1998-03-05 | 2006-02-02 | Chiron Corp., Emeryville | Verfahren zur verbesserung der serum-halbwertszeit von biologisch aktiven molekülen |
US6077508A (en) * | 1998-03-23 | 2000-06-20 | American Diagnostica Inc. | Urokinase plasminogen activator receptor as a target for diagnosis of metastases |
AU2003222668A1 (en) * | 2002-04-25 | 2003-11-10 | Rapidheal, Inc. | Growth factor delivery system for the healing of wounds and the prevention of inflammation and disease |
US20030203032A1 (en) * | 2002-04-25 | 2003-10-30 | Schultz Clyde L. | Growth factor delivery system for the healing of wounds and the prevention of inflammation and disease |
US20050074497A1 (en) * | 2003-04-09 | 2005-04-07 | Schultz Clyde L. | Hydrogels used to deliver medicaments to the eye for the treatment of posterior segment diseases |
US20050255144A1 (en) * | 2003-04-09 | 2005-11-17 | Directcontact Llc | Methods and articles for the delivery of medicaments to the eye for the treatment of posterior segment diseases |
US9216106B2 (en) | 2003-04-09 | 2015-12-22 | Directcontact Llc | Device and method for the delivery of drugs for the treatment of posterior segment disease |
WO2005110374A1 (en) * | 2004-04-30 | 2005-11-24 | Allergan, Inc. | Intraocular drug delivery systems containing a therapeutic component, a cyclodextrin, and a polymeric component |
TW200813091A (en) * | 2006-04-10 | 2008-03-16 | Amgen Fremont Inc | Targeted binding agents directed to uPAR and uses thereof |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5112755A (en) | 1982-04-15 | 1992-05-12 | Genentech, Inc. | Preparation of functional human urokinase proteins |
US4870008A (en) * | 1983-08-12 | 1989-09-26 | Chiron Corporation | Secretory expression in eukaryotes |
US4880734A (en) | 1984-05-11 | 1989-11-14 | Chiron Corporation | Eukaryotic regulatable transcription |
US4791068A (en) | 1984-06-22 | 1988-12-13 | Scripps Clinic And Research Foundation | Diagnostic assay for inhibitor of tissue-type and urokinase-type plasminogen activators |
US4751180A (en) | 1985-03-28 | 1988-06-14 | Chiron Corporation | Expression using fused genes providing for protein product |
EP0218696A4 (en) | 1985-04-15 | 1989-08-16 | Biotech Res Partners Ltd | ANTI-INFLAMMATORY PROTEIN FOR INHIBITION OF HUMAN PHOSPHOLIPASE. |
US5219569A (en) | 1985-04-22 | 1993-06-15 | Genentech, Inc. | Protease resistant urokinase |
US5376547A (en) | 1987-01-30 | 1994-12-27 | American Home Products Corporation | Des-epidermal growth factor plasminogen activators |
US4835255A (en) | 1987-03-26 | 1989-05-30 | Yale University | T-cell membrane protein |
US4999194A (en) | 1988-01-14 | 1991-03-12 | Collaborative Research, Inc. | Two-chain urokinase plasminogen activators for treatment of thrombotic disease |
DK182289D0 (da) | 1989-04-14 | 1989-04-14 | Francesco Blasi | Modifikation af proteiner |
ES2179036T3 (es) * | 1990-10-18 | 2003-01-16 | Cancerforskningsfonden Af 1989 | .nticuerpos contra el receptor uroquinasa y su uso |
JPH0595786A (ja) | 1991-10-07 | 1993-04-20 | Green Cross Corp:The | 変異ヒトプロウロキナーゼ |
US5340833A (en) | 1992-05-01 | 1994-08-23 | Eisai Co., Ltd. | Urokinase inhibitors |
US6120765A (en) | 1993-04-02 | 2000-09-19 | Shiseido Co. Ltd. | Urokinase plasminogen activator fragments |
AU682877B2 (en) * | 1993-05-28 | 1997-10-23 | Chiron Corporation | Peptide inhibitors of urokinase receptor activity |
AU7137994A (en) | 1993-06-01 | 1994-12-20 | Chiron Corporation | Expression of urokinase plasminogen activator inhibitors |
-
1994
- 1994-05-19 AU AU71379/94A patent/AU7137994A/en not_active Abandoned
- 1994-05-19 AT AT94920676T patent/ATE239085T1/de not_active IP Right Cessation
- 1994-05-19 DE DE69432608T patent/DE69432608T2/de not_active Expired - Fee Related
- 1994-05-19 EP EP94920676A patent/EP0802983B1/en not_active Expired - Lifetime
- 1994-05-19 KR KR1019950705328A patent/KR960702522A/ko not_active Application Discontinuation
- 1994-05-19 JP JP7500817A patent/JPH08508172A/ja not_active Ceased
- 1994-05-19 WO PCT/US1994/005669 patent/WO1994028145A2/en active IP Right Grant
- 1994-05-19 NZ NZ268470A patent/NZ268470A/en unknown
- 1994-05-19 CA CA002162855A patent/CA2162855A1/en not_active Abandoned
-
1995
- 1995-11-24 NO NO954778A patent/NO954778D0/no unknown
- 1995-11-27 FI FI955721A patent/FI955721A0/sv not_active Application Discontinuation
-
1998
- 1998-12-23 US US09/219,019 patent/US6268341B1/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
NO954778L (no) | 1995-11-24 |
US6268341B1 (en) | 2001-07-31 |
EP0802983B1 (en) | 2003-05-02 |
JPH08508172A (ja) | 1996-09-03 |
EP0802983A2 (en) | 1997-10-29 |
FI955721A (sv) | 1995-11-27 |
KR960702522A (ko) | 1996-04-27 |
WO1994028145A3 (en) | 1995-10-19 |
DE69432608T2 (de) | 2004-02-26 |
WO1994028145A2 (en) | 1994-12-08 |
NO954778D0 (no) | 1995-11-24 |
AU7137994A (en) | 1994-12-20 |
ATE239085T1 (de) | 2003-05-15 |
CA2162855A1 (en) | 1994-12-08 |
NZ268470A (en) | 1997-09-22 |
DE69432608D1 (de) | 2003-06-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FI955721A0 (sv) | Expression av inhibitorer för en plasminogen aktivator av urokinastyp | |
MY119155A (en) | New peptide derivatives | |
GR3033103T3 (en) | Peptidyl compounds and their therapeutic use as inhibitors of metalloproteinases | |
GB8909919D0 (en) | Small polypeptides | |
ES2185529T3 (es) | T-pa resistente a la serpina; mutante; genes. | |
HK1002457A1 (en) | Angiostatin fragments and methods of use | |
AP9200410A0 (en) | Retroviral protease inhibitors. | |
EP0604641A4 (en) | COMPOSITION CONTAINING AMINO DERIVATIVES OR RELATED TO BENZOIC ACID AMINES AND USES THEREOF, INCLUDING IN THE TREATMENT OF INFLAMMATORY DISEASES. | |
KR880701728A (ko) | 조직-형 및 우로키나제-형 플라스 미노겐 활성체 억제제의 진단검정 방법 및 억제제의 암호화 유전자 | |
DE69021885D1 (de) | Mutanten des menschlichen plasminogenaktivator-inhibitors 1 (pai-1), ihre herstellung und verwendung. | |
FI102844B1 (sv) | Förfarande för framställning av en förbättrad terapeutiskt aktiv aktivator för vävnadsplasminogen | |
MX9709340A (es) | Inhibidores de proteasa de serina derivados de imidazo (1,5a) piridina. | |
ATE266096T1 (de) | Mutant des inhibitors des erythrina caffra typs und dessen verwendung zur reinigung von serinproteasen | |
MX9603864A (es) | Uso de un inhibidor recombinante de erythrina caffra para la purificacion de serina proteasas. | |
MY105242A (en) | Anti-inflammatory 1-heteroaryl-3-acyl-2-oxindoles. | |
MX9700209A (es) | Uso medico de bromelaina. | |
NZ332903A (en) | Angiostatin fragments and aggregate angiostatin and methods for inhibiting endothelial cell proliferation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FD | Application lapsed |